

# Construction of a risk prediction model for subsequent bloodstream infection in intestinal carriers of carbapenem-resistant Enterobacteriaceae: a retrospective study in hematology department and intensive care unit

**Yue Wang**

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

**Qun Lin**

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

**Ju Zhong Chen**

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

**Yan Hong Hou**

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

**Na Shen**

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

**Feng Wang**

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

**Ziyong Sun** (✉ [zysun@tjh.tjmu.edu.cn](mailto:zysun@tjh.tjmu.edu.cn))

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

---

## Research

**Keywords:** Carbapenem-resistant Enterobacteriaceae, colonization, bloodstream infection, risk factor, risk prediction model

**DOI:** <https://doi.org/10.21203/rs.3.rs-65542/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Background

To establish a risk prediction model for carbapenem-resistant Enterobacteriaceae (CRE) bloodstream infection (BSI) in intestinal carriers.

## Methods

CRE screenings were performed every two weeks in hematology department and intensive care unit (ICU). Patients with positive CRE rectal swab screening were identified using electronic healthcare records from 15 May 2018 to 31 December 2019. All CRE strains were collected and identified. Carriers who developed CRE BSI were compared with those who did not develop CRE infection. The control group 1:1 stratified randomly matched the case group. Univariate logistic analysis, multivariate logistic analysis and stepwise regression analysis were carried out.

## Results

A total of 42 cases were included. Multivariate analysis showed that gastrointestinal injury (OR 86.82, 95%CI 2.58-2916.59,  $P = 0.013$ ), tigecycline exposure (OR 14.99, 95%CI 1.82-123.74  $P = 0.012$ ) and carbapenem resistance score (OR 11.24, 95% CI 1.81–69.70,  $P = 0.009$ ) were independent risk factors for CRE BSI in intestinal carriers ( $P < 0.05$ ). They were included in the Logistic regression model to predict BSI. According to receiver operating characteristic (ROC) curve analysis, the cut-off value of the model was 0.72, and the sensitivity, specificity and area under the curve (AUC) were 90.5%, 85.7% and 0.92, respectively.

## Conclusions

The risk prediction model based on gastrointestinal injury, tigecycline exposure and carbapenem resistance score of colonizing strain can effectively predict CRE BSI in patients with CRE colonization. Early CRE screening and detection for inpatients in key departments may early warning and reduce the risk of nosocomial infection of CRE.

## Background

Carbapenem-resistant Enterobacteriaceae (CRE) has attracted widespread attention due to its rapid growth, treatment difficulty, high mortality and high economic burden [1–3]. The course of CRE bloodstream infection (BSI) in immunocompromised patients is usually abrupt and fatal [4]. A cohort study of the impact of CRE infections on mortality of patients presenting with sepsis showed that

patients with CRE infections had significantly higher 30-day mortality: 63.8% versus 33.4% ( $P < 0.01$ ) [5]. Therefore, the study of CRE BSI has important clinical significance.

Studies have shown that CRE colonization is an independent risk factor for CRE infection [6]. Could we effectively prevent CRE infection by CRE de-colonization? It may take a lot of effort for little return. In fact, the majority of CRE carriers would not suffer from CRE infection. A retrospective study showed that only 16.5% (299/1806) of 1806 patients with CRE colonization subsequently developed CRE infection [7]. Excessive de-colonization will only lead to the waste of medical resources and the abuse of antibiotics.

WHO recommend surveillance cultures for asymptomatic CRE colonization should be performed, guided by local epidemiology and risk assessment [8]. Populations to be considered for such surveillance include patients with previous CRE colonization, patient contacts of CRE colonized or infected patients and patients with a history of recent hospitalization in endemic CRE settings [8]. Since 15th May 2018, our institute has carried out regular CRE screening for all inpatients in intensive care unit (ICU) and hematology department, two high-risk departments of CRE infection. It provided a very suitable observation population for this study. Standardized screening and isolation made the research results more valuable for clinical reference.

In previous studies, we found that the majority of CRE strains isolated from infection patients showed high-level carbapenems resistance. The minimum inhibitory concentrations (MICs) were  $> 32 \mu\text{g/ml}$ . The inhibition zone diameters of these strains were usually 6 mm. In contrast, the MIC value distribution of CRE strains isolated from rectal swabs were significantly different. Thus, we proposed the hypothesis that strains isolated from rectal swabs with high resistance to carbapenems might be associated with CRE infection. It is well known that the occurrence of infection depends on the interaction between pathogen and host. We aimed to establish a risk prediction model for CRE BSI subsequent CRE colonization simultaneously based on the pathogenic characteristics of colonized CRE strains and host risk factors, in order to early identify high-risk inpatients and prevent of CRE BSI infection.

## Methods

### Study design and setting

CRE infection control project has been carried out in hematology department and ICU since 15 May 2018 in a 6000 beds general teaching hospital in Wuhan, China. At the beginning of the project, all inpatients were screened and grouped. All the newly admitted patients were assessed according to the guidance from the European Centre for Disease Prevention and Control [9]. The patients who met the requirements were screened for CRE and reexamined regularly (**Fig.1**). We collected data from 15 May 2018 to 31 December 2019. Rectal swab CRE screening positive cases in hematology department and ICU were enrolled. CRE BSI was defined as isolation of CRE strains from one or more blood cultures and has clinical infection symptoms. Hospital admission was  $>48\text{h}$  from hospital admission to sepsis diagnosis. Patients with CRE BSI already, patients with spontaneous or drug-induced de-implantation, and patients with inconsistent positive results were excluded. The uninfected patients should be reexamined for CRE

screening at least once before discharge. Cases without reexamination should be excluded. Patients with CRE BSI subsequent to CRE intestinal colonization were included in the case group. Patients without secondary CRE infection were included in the control group. CRE intestinal colonization is defined as a positive result of CRE rectal swab screening without invasive infection.

## **Microbiology**

The rectal swabs were inoculated directly to a chromogenic agar plate containing carbapenem as selective agent (CHROMagar, France) for CRE screening. All the isolated bacteria were identified by MALDI-TOF mass spectrometer (Bruker Daltonics, USA). The sensitivity of meropenem and imipenem were detected by Kirby-Bauer method. The results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) M100-S29 breakpoints.

## **Variables and definitions**

The data were collected through case review and laboratory record. Variables possibly related to BSI were collected: General information (gender, age, department), underlying conditions (hypertension, diabetes, tumor, impaired immune function, gastrointestinal injury), invasive procedures and devices (solid organ transplantation, hematopoietic stem cell transplantation, surgery, mechanical ventilation, central venous catheter, urinary catheter, gastric tube, drainage tube), antibiotic exposure, length of stay from CRE screening to outcome (occurrence of CRE BSI or discharge), colonizing bacteria and carbapenem resistance score, etc.

Impaired immune function included receiving radiotherapy and chemotherapy, agranulocytosis, long-term or massive hormone therapy, and HIV infection. Gastrointestinal injury included gastrointestinal bleeding or perforation, ostomy or excision of stomach and intestine, gastroenteritis, cholecystitis and pancreatitis. Antibiotic exposure and duration were considered from CRE screening to CRE BSI onset for the case group, or to hospital discharge for the control group.

The inhibition zone diameters of meropenem and imipenem were discontinuous numerical variables, so we used carbapenem resistance score as a categorical variable to represent the resistance of carbapenems. When the inhibition zone diameters of meropenem and imipenem were both >6mm, it was recorded as "1"; when either the inhibition zone diameter of meropenem or the inhibition zone diameter of imipenem was equal to 6mm, it was recorded as "2"; when the diameter of meropenem and imipenem were both equal to 6mm, it was recorded as "3".

## **Statistical analysis**

Carriers who developed CRE BSI were compared with those who did not develop CRE infection. Pearson chi-square test was used for binary data. Nonparametric Mann-Whitney rank sum test was used for ordered categorical data. T-test was used for measurement data. The variables with  $P < 0.05$  in univariate analysis were included in multivariate analysis. Then stepwise regression analysis was carried out to determine the parameters in the risk prediction model and establish the logistic regression model. The OR

value and 95% confidence interval of each factor were calculated. The receiver operating characteristic (ROC) curve was used to evaluate the predictive ability of the model.

## Results

### Patient cohort

During the study period, 12754 rectal swabs (7456 inpatients) were screened. 860 patients being admitted to hematology department and ICU with positive CRE rectal swab screening were identified. After exclusion criteria were applied, a total of 73 patients met the standard. 21 patients developed CRE BSI were included in the case group, matched with 21 patients who did not have CRE infection with 1:1 matching ratio (**Fig.1**).

### Strains and carbapenem resistance score

Among 42 colonized bacteria, 31 (73.8%) were *Klebsiella pneumoniae*, 9 (21.4%) were *Escherichia coli*, 2 (4.8%) were *Citrobacter* spp.. There were 18 cases of *Klebsiella pneumoniae* in the case group, accounting for 85.7%, while there were 13 cases of *Klebsiella pneumoniae* in the control group, accounting for 61.9%. There was no statistical difference between the two groups ( $P=0.079$ ).

In total, Carbapenem resistance score was "3" in 23 cases (54.8%), "2" in 5 cases (11.9%), "1" in 14 cases (33.3%). In the case group, the score was "3" in 17 cases (81.0%), "1" in 3 cases (14.3%); In the control group, the score was "3" in 6 cases (28.6%), "1" in 11 cases (52.4%). There was a significant difference between the two groups ( $P<0.05$ ).

**Fig.2** showed distribution of carbapenem resistance score and colonizing bacteria in case group and control group.

### Independent risk factors of CRE BSI in intestinal carriers

Univariate and multivariate logistic regression analysis was used to analyze the variables. The results are shown in Table 1. Gastrointestinal injury, tigecycline exposure and carbapenem resistance score were independent risk factors for CRE BSI in intestinal carriers ( $P<0.05$ ).

### The time for patients to develop CRE BSI

The median time from positive screening to CRE BSI was 13 days (range from 1 to 202) (**Table 1**).

### Development of CRE BSI risk prediction model

Stepwise logistic regression analysis showed that gastrointestinal injury (OR 86.82, 95%CI 2.58-2916.59,  $P=0.013$ ), tigecycline exposure (OR 14.99, 95%CI 1.82-123.74  $P=0.012$ ) and carbapenem resistance score (OR 11.24, 95% CI 1.81-69.70,  $P=0.009$ ) were valuable for risk prediction model of CRE BSI (**Table 2**). The logistic regression model was established as follows:

$PV = 1 / (1 + e^{-(-8.488 + 4.464 \times \text{gastrointestinal injury} + 2.707 \times \text{tigecyclin exposure} + 2.419 \times \text{carbapenem resistance score})})$

**Abbreviation:** PV, predictive value; e, natural logarithm

**Variable:** carbapenem resistance score, it was given 1, 2 or 3 according to the inhibition zone diameter; gastrointestinal injury, “Yes” and “No” were given 1 and 0, respectively.

### **Validation of the risk prediction model**

By ROC curve analysis (Fig.3), area under the curve (AUC) was 0.92. The cut off value of the model was 0.72. The sensitivity and specificity of the model were 90.5% and 85.7% respectively.

## **Discussion**

Of the 7456 patients screened for CRE, 860 found CRE colonization, with the colonization rate of 11.5%. Among all CRE colonizers, only 2.4% (21/860) had subsequent CRE BSI, of which 57.1% (12/21) had adverse outcomes. Whether and when CRE colonizers need to be de-colonization is a clinical unsolved puzzle. Due to the critical consequences of CRE bloodstream infection, our study focused on the identification of high-risk patients with CRE bacteremia to provide a theoretical basis for de-colonization.

Patients with hematologic malignancies and hematopoietic stem cell transplant recipients are at high risk of developing invasive infections due to enteric bacteria because of chemotherapy-induced neutropenia and gastrointestinal mucositis [10]. In fact, gastrointestinal mucositis is a complex inflammatory reaction of the mucous membranes, a side effect of both chemotherapy and radiotherapy [11]. Its severity is difficult to assess. Interestingly, we found that gastrointestinal injury with definite diagnosis including gastrointestinal bleeding or perforation, ostomy or excision of stomach and intestine, gastroenteritis, cholecystitis and pancreatitis was an independent risk factor and could be included in the model for risk assessment of CRE BSI in CRE carriers.

Tigecycline has a large volume of distribution and high concentration in gallbladder, colon and pulmonary tissue. In contrast, the serum concentrations of tigecycline are relatively low [12]. After a single 100 mg dose of tigecycline, serum concentrations of tigecycline rapidly declined from a mean value of 1.94 mg/L to 0.31 mg/L between 3 min and 1 h after the end of the infusion. The subsequent concentrations in serum slowly declined to mean values of 0.22 ng/mL and 0.07 mg/L at 4 and 24 h after the start of the tigecycline infusion [12]. Tigecycline is not approved for the treatment of BSI because its serum concentrations are generally deemed not adequate. Therefore, conventional dose of tigecycline (100 mg initially, followed by 50 mg q12h) cannot prevent CRE BSI. In addition, tigecycline has a wide antibacterial spectrum, which is active against a wide range of Gram-positive and -negative aerobic and anaerobic bacteria [13]. In most large-scale monitoring studies, the sensitivity of tigecycline in Enterobacteriaceae is kept at a high level of > 90% [14–16]. CRE isolates also showed high susceptibility to tigecycline (89.7%) [17]. It should be noted that tigecycline resistance rate of Klebsiella

pneumoniae in hematopoietic stem cell transplant patients can reach 16% [18]. Taken together, we inferred that tigecycline exposure increased the risk of CRE BSI might due to intestinal flora disorder.

There were few studies on the correlation between bacterial characteristics of colonized CRE and the subsequent occurrence of infection currently. Giannella M et al established a prediction model of carbapenem-resistant *Klebsiella pneumoniae* (CR-KP) BSI following CRKP colonization, based on whether there was ICU admission, radiotherapy and chemotherapy, abdominal invasive operation and multi-site CR-KP colonization [19]. The sensitivity and specificity were 93% and 42% respectively. In our study, what makes sense is that three significant variables which included carbapenem resistance score of colonizing CRE were screened out to establish the risk prediction model for subsequent BSI in intestinal carriers of CRE. The sensitivity and specificity of the model were 90.5% and 85.7% respectively. It suggested that the drug resistance of colonizing bacteria is closely related to the occurrence of infection.

Carbapenem resistance score was given according to the inhibition zone diameter instead of MIC. The advantage is that it can be evaluated at the same time as the CRE screening. Rectal swabs could be directly inoculated into MacConkey agar medium, then the paper disks of meropenem and imipenem could be pasted in the original area. It greatly simplifies the detection and evaluation process, and is helpful for the promotion and use of the model. However, it should be noted that the number of cases is small and the model is currently only suitable for hematology department and ICU. Further studies are still needed.

## Conclusions

To summarize, gastrointestinal injury, tigecycline exposure and carbapenem resistance score of colonizing bacteria can effectively predict the risk of subsequent BSI in CRE carriers. Our findings suggested that carbapenem susceptibility test of colonized bacteria in critical patients can identify patients at high risk of CRE infection and prevent them from CRE infection as early as possible. The application of this risk prediction model may reduce the incidence and mortality of CRE infection. It may also avoid unnecessary use of antibiotics in low-risk groups to reduce the selective pressure of antibiotics, and further reduce the production of CRE.

## Abbreviations

CRE carbapenem-resistant Enterobacteriaceae

BSI bloodstream infection

ICU intensive care unit

ROC receiver operating characteristic

AUC area under the curve

MICs minimum inhibitory concentrations

PV predictive value

CR-KP carbapenem-resistant *Klebsiella pneumoniae*

## **Declarations**

## **Ethics approval and consent to participate**

The study was approved by the ethical committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. The data are anonymous, and the requirement for informed consent was therefore waived.

### **Consent for publication**

Written informed consent for publication was obtained from all participants.

### **Availability of data and materials**

All data generated or analysed during this study are included in this published article [and its supplementary information files].

### **Competing interests**

We declare no competing interests.

## **Funding**

National Mega Project on Major Infectious Disease Prevention (2017ZX10103005-007) and Natural Science Foundation of Hubei Province(2019CFB666).

## **Authors' contributions**

Ziyong Sun contributed to the conception of the study. Qun Lin performed the experiment. Zhongju Chen collected data. Hongyan Hou and Feng Wang contributed significantly to analysis and manuscript preparation. Yue Wang performed the data analyses and wrote the manuscript. Na Shen helped perform the analysis with constructive discussions.

## **Acknowledgements**



This study was supported by the National Mega Project on Major Infectious Disease Prevention (2017ZX10103005-007) and Natural Science Foundation of Hubei Province(2019CFB666).

## References

1. Centers For Disease Control And Prevention, USA. Antibiotic resistance threats in the United States, 2013. 2013. [https://www.cdc.gov/drugresistance/biggest\\_threats.html](https://www.cdc.gov/drugresistance/biggest_threats.html). Accessed 23 April 2013.
2. Peri AM, Doi Y, Potoski BA, Harris PNA, Paterson DL, Righi E. Antimicrobial treatment challenges in the era of carbapenem resistance. *Diagn Microbiol Infect Dis*. 2019;94:413–25.
3. Bartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. *Clin Microbiol Infect*. 2017;23:48.e9-48.e16.
4. Jaiswal SR, Gupta S, Kumar RS, Sherawat A, Rajoreya A, Dash SK, et al. Gut Colonization with Carbapenem-resistant Enterobacteriaceae Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of A Prospective Surveillance Study. *Mediterr J Hematol Infect Dis*. 2018;10:e2018025.
5. Sabino S, Soares S, Ramos F, Moretti M, Zavascki AP, Rigatto MH. A Cohort Study of the Impact of Carbapenem-Resistant *Enterobacteriaceae* Infections on Mortality of Patients Presenting with Sepsis. *mSphere*. 2019;4:e00052-19.
6. McConville TH, Sullivan SB, Gomez-Simmonds A, Whittier S, Uhlemann AC. Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. *PLoS One*. 2017;12:e0186195.
7. Tischendorf J, de Avila RA, Safdar N. Risk of infection following colonization with carbapenem-resistant Enterobacteriaceae: A systematic review. *Am J Infect Control*. 2016;44:539–43.
8. World Health Organization. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in health care facilities. 2017. <https://www.who.int/infection-prevention/publications/guidelines-cre/en/>.
9. Magiorakos AP, Burns K, Rodríguez Baño J, Borg M, Daikos G, Dumpis U, et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant *Enterobacteriaceae* into healthcare settings: guidance from the European Centre for Disease Prevention and Control. *Antimicrob Resist Infect Control*. 2017;6:113.
10. Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. *Virulence*. 2017;8:391–402.
11. Kuiken NSS, Rings EHHM, Blijlevens NMA, Tissing WJE. Biomarkers and non-invasive tests for gastrointestinal mucositis. *Support Care Cancer*. 2017;25:2933–41.
12. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. *J Antimicrob Chemother*.

- 2006;58:1221–9.
13. Frampton JE, Curran MP. Tigecycline Drugs. 2005;65:2623–37.
  14. Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). *Diagn Microbiol Infect Dis*. 2013;76:217–21.
  15. Decousser JW, Woerther PL, Soussy CJ, Fines-Guyon M, Dowzicky MJ. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016. *Antimicrob Resist Infect Control*. 2018;7:68.
  16. Liu XJ, Lyu Y, Li Y, Xue F, Liu J. Trends in Antimicrobial Resistance against Enterobacteriaceae Strains Isolated from Blood: A 10-year Epidemiological Study in Mainland China (2004–2014). *Chin Med J (Engl)*. 2017;130:2050–5.
  17. Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R, et al. Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012–2016). *Clin Infect Dis*. 2018;67:196–205.
  18. Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez SSL, et al. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. *Clin Infect Dis*. 2017;65:1819–28.
  19. Giannella M, Treccarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE, et al. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* bloodstream infection among rectal carriers: a prospective observational multicentre study. *Clin Microbiol Infect*. 2014;20:1357–62.

## Tables

**Table 1** Univariate and multivariate analysis of risk factors for subsequent BSI in CRE intestinal carriers

| Variable                  |   | Infection group<br>N=21(%) | Non-infection group<br>N=21(%) | Univariable<br>P value <sup>ab</sup> | Multivariable<br>P value <sup>b</sup> |
|---------------------------|---|----------------------------|--------------------------------|--------------------------------------|---------------------------------------|
| <b>Patient factors</b>    | <b>General information</b>              |                            |                                |                                      |                                       |
|                           | Male                                    | 12(57.1)                   | 12(57.1)                       | 1.000                                | 0                                     |
|                           | Age, median                             | 45(17-62)                  | 51(17-91)                      | 0.161                                | 0                                     |
|                           | ICU                                     | 12(57.1)                   | 12(57.1)                       | 1.000                                | 0                                     |
|                           | <b>Underlying conditions</b>            |                            |                                |                                      |                                       |
|                           | Hypertension                            | 8(38.1)                    | 5(23.8)                        | 0.317                                | 0                                     |
|                           | Diabetes                                | 4(19.0)                    | 6(28.6)                        | 0.469                                | 0                                     |
|                           | Tumor <sup>c</sup>                      | 8(40.0)                    | 9(45.0)                        | 0.749                                | 0                                     |
|                           | Impaired immune function                | 9(42.9)                    | 9(42.9)                        | 1.000                                | 0                                     |
|                           | Gastrointestinal injury <sup>d</sup>    | 9(42.9)                    | 2(9.5)                         | 0.014                                | 0.013                                 |
|                           | <b>Invasive procedures and devices</b>  |                            |                                |                                      |                                       |
|                           | Solid organ transplantation             | 1(4.8)                     | 2(9.5)                         | 0.549                                | 0                                     |
|                           | Hematopoietic stem cell transplantation | 3(14.3)                    | 3(14.3)                        | 1.000                                | 0                                     |
|                           | Surgery                                 | 8(38.1)                    | 10(47.6)                       | 0.533                                | 0                                     |
|                           | Mechanical ventilation                  | 12(57.1)                   | 9(42.9)                        | 0.355                                | 0                                     |
|                           | Central venous catheter                 | 19(90.5)                   | 17(81.0)                       | 0.378                                | 0                                     |
|                           | Urinary catheter                        | 12(57.1)                   | 12(57.1)                       | 1.000                                | 0                                     |
|                           | Gastric tube                            | 11(52.4)                   | 11(52.4)                       | 1.000                                | 0                                     |
|                           | Drainage tube                           | 15(71.4)                   | 9(42.9)                        | 0.061                                | 0                                     |
|                           | <b>Antibiotic exposure<sup>e</sup></b>  |                            |                                |                                      |                                       |
|                           | Exposure                                |                            | 21(100.0)                      | 21(100.0)                            |                                       |
| Drug combination          |   | 21(100.0)                  | 20(95.2)                       | 0.311                                | 0                                     |
| <b>Antibiotic classes</b> |   |                            |                                |                                      |                                       |
| Cephalosporins            | Exposure                                | 4(19.0)                    | 5(23.8)                        | 0.707                                | 0                                     |
|                           | Days of                                 | 0(0-16)                    | 0(0-8)                         | 0.921                                | 0                                     |

|                                 |                              |                     |         |       |       |  |
|---------------------------------|------------------------------|---------------------|---------|-------|-------|--|
|                                 |                              | exposure,<br>median |         |       |       |  |
| β-lactam/β-lactamase inhibitors | Exposure                     | 15 71.4             | 15 71.4 | 1.000 |       |  |
|                                 | Days of exposure, median     | 8 0-116             | 9 0-43  | 0.780 |       |  |
| Aminoglycosides                 | Exposure                     | 1 4.8               | 2 9.5   | 0.549 |       |  |
|                                 | Days of exposure, median     | 0 0-2               | 0 0-24  | 0.244 |       |  |
| Fluoroquinolones                | Exposure                     | 12 57.1             | 13 61.9 | 0.753 |       |  |
|                                 | Days of exposure, median     | 4 0-95              | 5 0-35  | 0.947 |       |  |
| Carbapenems                     | Exposure                     | 17 81.0             | 13 61.9 | 0.172 |       |  |
|                                 | Days of exposure, median     | 4 0-26              | 4 0-19  | 0.718 |       |  |
| Tegacyclin                      | Exposure <sup>d</sup>        | 17 81.0             | 9 42.9  | 0.011 | 0.012 |  |
|                                 | Days of exposure, median     | 5 0-15              | 0 0-26  | 0.730 |       |  |
| Polymyxin B                     | Exposure                     | 1 4.8               | 2 9.5   | 0.549 |       |  |
|                                 | Days of exposure, median     | 0 0-10              | 0 0-9   | 0.941 |       |  |
| TMP/SMX <sup>f</sup>            | Exposure                     | 1 4.8               | 3 14.3  | 0.293 |       |  |
|                                 | Days of exposure, median     | 0 0-6               | 0 0-35  | 0.229 |       |  |
| Glycopeptides                   | Exposure                     | 4 19.0              | 6 28.6  | 0.469 |       |  |
|                                 | Days of exposure, median     | 0 0-13              | 0 0-18  | 0.207 |       |  |
| <b>Strain factors</b>           | <b>Colonizing bacteria</b>   |                     |         | 0.101 |       |  |
|                                 | <i>Klebsiella pneumoniae</i> | 18 85.7             | 13 61.9 | 0.079 |       |  |
|                                 | <i>Escherichia coli</i>      | 2 9.5               | 7 33.3  | 0.060 |       |  |
|                                 | Other Enterobacteriaceae     | 1 4.8               | 1 4.8   | 1.000 |       |  |

|                |   | Carbapenem resistance score <sup>d</sup> |          | 0.001 | 0.009 |
|----------------|---|--|----------|-------|-------|
|                | 1   | 3[14.3]                                  | 11[52.4] | 0.009 |       |
|                | 2   | 1[4.8]                                   | 4[19.0]  | 0.153 |       |
|                | 3   | 17[81.0]                                 | 6[28.6]  | 0.001 |       |
| <b>Outcome</b> | <b>Days from screening to outcome (infection / discharge), median</b> | 13[1-202]                                | 18[4-60] | 0.784 |       |


1. According to the type of data, the appropriate analysis method was selected. Pearson chi-square test was used for binary data. Nonparametric Mann-Whitney rank sum test was used for ordered categorical data. T-test was used for measurement data.
2.  $P < 0.05$  was considered statistically significant.
3. Including solid organ tumors and hematogenous malignancies.
4. These variables were  $P < 0.05$  in univariate analysis, and then were included in the multivariate analysis.
5. These variables were considered from CRE screening to CRE BSI onset for cases, or to hospital discharge for controls
6. TMP/SMX, sulfamethoxazole and trimethoprim

**Table 2** Risk factors of subsequent BSI in CRE intestinal carriers using binary logistic regression analysis

| Independent variables          | B      | S.E.  | Wald  | df | Sig.  | Exp(B) | 95% CI for EXP(B) |          |
|--------------------------------|--------|-------|-------|----|-------|--------|-------------------|----------|
|                                |        |       |       |    |       |        | Lower             | Upper    |
| Gastrointestinal mucosa damage | 4.464  | 1.793 | 6.198 | 1  | 0.013 | 86.819 | 2.584             | 2916.592 |
| Tegacyclin exposure            | 2.707  | 1.077 | 6.321 | 1  | 0.012 | 14.991 | 1.816             | 123.737  |
| Carbapenem resistance score    | 2.419  | 0.931 | 6.749 | 1  | 0.009 | 11.236 | 1.811             | 69.700   |
| Constant                       | -8.488 | 2.971 | 8.164 | 1  | 0.004 | 0.000  |                   |          |


Note: Nagelkerke  $R^2=0.700$ .

## Figures




**Figure 1**

CRE screening, enrollment and follow-up \*Patients in the control group were selected using stratified random sampling according to the departments to ensure that all the departments were represented.



**Figure 2**

Distribution of carbapenem resistance score and colonizing bacteria in case group and control group X axis is number of strains, Y axis is the score of carbapenem resistance. \* Klebsiella pneumoniae with carbapenem resistance score 3 accounted for 94.4% (17/18) of all Klebsiella pneumoniae in the case group and 46.2% (6/13) in the control group. There was a significant difference between the two groups (P = 0.002). \*\*Klebsiella pneumoniae with carbapenem resistance score 1 accounted for 5.6% (1/18) of all Klebsiella pneumoniae in the case group and 53.8% (7/13) in the control group. There was a significant difference between the two groups (P = 0.002). # Klebsiella pneumoniae accounted for 100% (17/17) of all strains with carbapenem resistant score 3 in the case group and 100% (6/6) in the control group. There was no statistical difference between the two groups. ##Klebsiella pneumoniae accounted for 33.3% (1/3) of all strains with carbapenem resistant score 1 in the case group and 63.6% (7/11) in the control group. There was no statistical difference between the two groups (P = 0.347).



**Figure 3**

ROC curve analysis was performed to evaluate the predictive ability of risk prediction model AUC=0.92, cut-off value = 0.72, sensitivity = 90.5%, specificity = 85.7%.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1.xls](#)